Abilify Side Effects: Akathisia, Weight, and Impulse Control

Your prescriber added a small dose of Abilify to your antidepressant, and two weeks later you can’t sit through a TV show. Or you’ve noticed something harder to name, like a pull toward online betting or late-night shopping that doesn’t feel like you. Both are known Abilify side effects, and both are easy to miss if no one tells you what to watch for.

Aripiprazole, the drug in Abilify, doesn’t simply block dopamine the way older antipsychotics do. According to the Abilify prescribing information, it partly activates dopamine D2 and serotonin 5-HT1A receptors while blocking serotonin 5-HT2A receptors. Knowing which receptors it touches, with that much precision, helps make sense of side effects that don’t look like those of older antipsychotics.

Abilify’s safety record is extensive. Its label draws on more than 13,000 adults in clinical trials, and it’s FDA-approved as an add-on treatment for depression as well as for schizophrenia, bipolar mania, and other conditions. A network meta-analysis of 18 antipsychotics ranked aripiprazole among the most metabolically benign options. The data are real, and the science is well established.

But Abilify’s two boxed warnings and its impulse-control warning are easy to misread, and at Siggy we’d rather walk you through what each one covers, who it applies to, and what to watch for. This guide explains akathisia and its timing, what weight change looks like over a year, the 2016 FDA impulse-control warning, and both boxed warnings in plain language. Reading them clearly keeps each decision grounded in evidence.

What This Page Covers

• What Are the Most Common Abilify Side Effects?
• What Does Abilify Akathisia Feel Like?
• Does Abilify Cause Weight Gain?
• What Is the FDA Impulse-Control Warning?
• What Do Abilify’s Boxed Warnings Mean?
• Other Serious Risks and Interactions
• When to Call Your Prescriber or 911

What Are the Most Common Abilify Side Effects?

Across adult trials, the label lists nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, and restlessness as the most common side effects, each affecting 10% or more of people. When Abilify was added to an antidepressant for 6 weeks, these stood out compared with placebo:

• Akathisia: 25% versus 4%
• Restlessness: 12% versus 2%
• Insomnia: 8% versus 2%
• Fatigue: 8% versus 4%
• Blurred vision: 6% versus 1%
• Constipation: 5% versus 2%

Akathisia rates depend heavily on why Abilify is prescribed. Here’s how often the label reports it in adult trials, compared with placebo:

Use	Abilify	Placebo
Schizophrenia	8%	4%
Bipolar mania, alone	13%	4%
Bipolar mania, with lithium or valproate	19%	5%
Depression, added to an antidepressant	25%	4%

That spread matters. Many side effect summaries quote the 8% schizophrenia figure, but people taking Abilify for depression reported akathisia about three times as often.

What Does Abilify Akathisia Feel Like?

Akathisia is an inner restlessness that makes it hard to stay still. A Canadian clinical guideline on akathisia describes a sense of mental unease and dysphoria, with restlessness you can both feel and see, and notes it has been linked with suicidal thinking in some groups, though how much it raises that risk is uncertain. It’s easy to mistake for worsening anxiety or depression.

Timing is the best clue. In a pooled analysis of two add-on depression trials, 76% of akathisia cases began in the first 3 weeks, 92% were mild to moderate, and only 0.8% of people stopped Abilify because of it. Age was the only predictor the authors found: adults 18 to 40 were more likely to develop it.

The guideline’s first steps involve the medication itself, such as considering a lower dose or a switch. If an add-on is needed, it calls propranolol the first-choice option, with low-dose mirtazapine as an alternative. These are prescriber decisions, since each option has its own risks. If a new, driven restlessness shows up after starting Abilify or raising the dose, tell your prescriber promptly, and if it comes with thoughts of suicide, call or text 988. Latuda can cause akathisia too, and our guide to Latuda side effects walks through how it’s managed.

Does Abilify Cause Weight Gain?

Abilify is gentler on metabolism than many antipsychotics, but weight gain is real. In the label’s 6-week add-on depression trials, people gained an average of 1.7 kg (about 3.7 pounds) versus 0.4 kg on placebo, and 5.2% gained 7% or more of their body weight, compared with 0.6% on placebo. Fasting triglycerides rose from normal to high in 9.7% versus 4.1%, while fasting glucose changes were similar to placebo.

Longer use tells a fuller story. In a 52-week open-label study of add-on Abilify in about 1,000 adults with depression, average weight gain was 4.4 kg, and 36.6% of those measured at the end had gained 7% or more. The study had no placebo group, and only about a third of participants completed the full year.

Children and teens can gain more. In the label’s trials for autism-related irritability, 26.3% of young people gained 7% or more of their body weight, versus 7.1% on placebo. Whatever your age, the label calls for monitoring weight, blood sugar, and lipids. Our guide to tracking Abilify side effects month by month lays out a practical schedule.

What Is the FDA Impulse-Control Warning?

On May 3, 2016, the FDA issued a Drug Safety Communication on aripiprazole, warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex had been reported. A search of reports since the drug’s 2002 approval found 184 cases. Pathological gambling made up 164 of them, with smaller numbers involving compulsive sexual behavior, buying, eating, or several problems at once.

The pattern in those reports is what makes the warning useful. In all 167 U.S. cases, the urges began only after starting aripiprazole and resolved within days to weeks of lowering the dose or stopping. The FDA called these problems rare, noting that about 1.6 million people filled an aripiprazole prescription in 2015, and it flagged people with a personal or family history of obsessive-compulsive disorder, impulse-control problems, bipolar disorder, impulsive personality, or alcohol or drug use problems for closer watching.

Population data point the same way. A nested case-control study in a large U.S. claims database found aripiprazole users had about 5 times the rate of newly diagnosed gambling disorder and nearly 8 times the rate of impulse control disorder compared with nonusers. That design shows an association, not proof of cause, and the confidence ranges were wide.

The label adds a practical point: people often don’t recognize these urges as a side effect, so prescribers should ask about them directly. Telling a partner or close friend what to look for, like unusual spending or late-night betting, can help. Don’t stop Abilify suddenly on your own, and talk with your prescriber as soon as you notice a change.

What Do Abilify’s Boxed Warnings Mean?

A boxed warning is the FDA’s strongest label warning. Abilify has two, and they apply to specific groups.

The first covers older adults with dementia-related psychosis, who face an increased risk of death on antipsychotics. Abilify isn’t approved for that use. A meta-analysis of 15 placebo-controlled trials of newer antipsychotics in dementia, including three with aripiprazole, found deaths in 3.5% on the drugs versus 2.3% on placebo over trials that generally ran 10 to 12 weeks. The label also reports more strokes and related events in aripiprazole’s dementia trials.

The second warning applies because Abilify is used alongside antidepressants. In pooled antidepressant trials summarized in the label, suicidal thoughts and behaviors rose by about 14 additional cases per 1,000 people under 18 and 5 per 1,000 ages 18 to 24, with no increase from 25 to 64 and a decrease at 65 and older. The label calls for close monitoring of everyone, especially in the first few months and after any dose change. Abilify isn’t approved to treat depression in children and teens.

Other Serious Risks and Interactions

The label lists several less common but important risks:

• Tardive dyskinesia: involuntary movements, often of the face or tongue, that can become permanent, with risk thought to rise with longer use and higher total dose. In the year-long study, 0.4% had possible cases, all resolving within 45 days of stopping.
• Neuroleptic malignant syndrome: a rare emergency with high fever, muscle rigidity, confusion, and unstable pulse or blood pressure.
• Dizziness on standing, falls, and trouble with heat regulation, which call for care in hot weather or with dehydration.
• Seizures: 0.1% of adults in short-term trials, so caution is advised with a seizure history.
• Lower milk supply: exposure during pregnancy or after birth may reduce breast milk, so infants who are breastfed should be watched for weight gain.

Drug interactions matter, too. Abilify is broken down by the liver enzymes CYP2D6 and CYP3A4, and the label usually halves the dose with strong blockers such as fluoxetine, paroxetine, or clarithromycin. As an add-on for depression, though, the label says to use the standard add-on dosing without that adjustment.

When to Call Your Prescriber or 911

Call 911 for a high fever with stiff muscles and confusion, a seizure, fainting, or trouble breathing. Call or text 988 for thoughts of suicide or self-harm. Contact your prescriber promptly for:

• Restlessness that makes it hard to sit still
• New urges to gamble, spend, eat, or have sex that feel hard to control
• Involuntary movements of the face, lips, or tongue
• Increased thirst, urination, or hunger, which the label lists as signs of high blood sugar
• New or worsening depression, anxiety, or irritability, especially after a dose change

Don’t stop Abilify abruptly without talking to your prescriber.

With Abilify, the side effects that matter most, restlessness in the first weeks and new urges that creep in quietly, are exactly the ones a quarterly visit can miss.

Abilify’s side effects follow a readable pattern: akathisia comes early and is most common in depression, weight gain is modest in the short term but worth tracking over a year, and impulse-control urges are rare but often reversible when caught. The boxed warnings apply to specific groups, and knowing which one fits you makes monitoring more focused. If you’re weighing when a medication change should start to help, our guide to how long Abilify takes to work covers the timeline.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Don’t start, change, or stop a medication without talking to your prescriber, except in an emergency described here. It was reviewed for clinical accuracy and reflects sources available as of September 2026.